Biomarkers of prognosis in patients with differentiated thyroid cancer: Results from the DECISION trial.
2016
6059Background: Sorafenib (SOR) is a multikinase inhibitor approved to treat locally recurrent or metastatic, progressive, differentiated thyroid cancer (DTC) refractory to radioactive iodine treat...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
4
Citations
NaN
KQI